YOLFTbeta
APT Medical Inc

APT Medical Inc

688617 · SHG · Healthcare / Medical Devices

286.87CNY+8.55 (+3.07%)

Price History

Full chart

Market Stats

Previous Close278.32
Open276.96
Day Range274.80 – 291.88
52-Week Range176.28 – 335.81
Volume1.40M
Market Cap35.13B
P/E (TTM)37.61
Forward P/E0.00
EPS6.60
Dividend Yield0.40%
Beta-0.37
50-Day Avg235.71
200-Day Avg230.87

About

APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China. It offers electrophysiology products, such as navigation systems, navigated catheters, mapping catheters, ablation catheters, transseptal needles and sheaths, and steerable sheaths; and interventional cardiology and peripheral products, including access, diagnostic products, therapeutic products, and accessories. The company also manufactures and supplies EP and vascular intervention medical devices. In addition, it provides OEM and ODM services comprising project design and development, customization, and volume OEM; and customized products consisting of catheters, guidewires, and delivery systems, as well as nitinol products in cardiology, peripheral, neurology, and urology. APT Medical Inc. was founded in 2002 and is headquartered in Shenzhen, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Zhenghui Cheng
  • Employees3.40K
  • HeadquartersBuilding B, Tongfang Information Port, Shenzhen, China, 518000, China
  • Websitehttps://www.aptmed.com

Leadership

  • Mr. Zhenghui ChengPresident, GM & Vice Chairman · b. 1964
  • Ms. Qi Han GuiFinancial Officer · b. 1980
  • Mr. Zhenhua DaiDeputy GM & Employee Representative Director · b. 1968
  • Mr. Yuchen QiuDeputy General Manager · b. 1965
  • Mr. Yonggui HanDeputy General Manager · b. 1963
  • Mr. Fangyuan LiuDeputy General Manager · b. 1976
  • Mr. Wei WangDeputy General Manager · b. 1971
  • Mr. Wang JinheDeputy General Manager · b. 1974
  • Ye Hui ChenAccounting Supervisor

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue153.17M241.77M403.96M479.44M828.69M1.22B1.65B2.07B2.58B
Growth (%)-+57.84%+67.08%+18.68%+72.85%+46.74%+35.71%+25.18%+25.08%
Cost of Revenue47.77M75.48M118.16M142.13M259.08M354.04M486.14M579.89M700.84M
Gross Profit105.41M166.29M285.80M337.30M569.61M861.98M1.16B1.49B2.58B
Gross Margin68.81%68.78%70.75%70.35%68.74%70.89%70.54%71.93%100.00%
Operating Expense74.29M142.69M193.71M217.86M347.11M464.99M563.66M732.22M1.64B
Operating Income31.12M23.60M92.09M119.45M222.50M396.99M600.41M753.69M943.93M
Operating Margin20.32%9.76%22.80%24.91%26.85%32.65%36.38%36.48%36.53%
EBITDA38.98M32.60M106.29M142.19M251.16M437.51M656.42M824.98M1.01B
EBITDA Margin25.45%13.48%26.31%29.66%30.31%35.98%39.78%39.93%39.20%
Net Income34.48M21.51M82.57M110.78M207.92M358.02M533.92M673.15M820.64M
Net Income Margin22.51%8.90%20.44%23.11%25.09%29.44%32.35%32.59%31.76%
R&D49.98M53.38M70.42M71.90M134.88M174.88M237.92M290.54M364.80M
R&D as % of Total Revenue32.63%22.08%17.43%15.00%16.28%14.38%14.42%14.06%14.12%
Interest Expense461.19K268.26K257.57K976.97K1.80M1.68M4.01M2.35M1.46M
Interest Expense % of Total Revenue0.30%0.11%0.06%0.20%0.22%0.14%0.24%0.11%0.06%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets252.74M325.82M561.03M588.71M2.01B2.23B2.57B2.98B3.66B
Total Liabilities38.31M55.12M215.13M138.62M222.02M434.91M610.98M425.85M477.40M
Total Equity214.18M269.84M349.59M460.36M1.78B1.76B1.91B2.52B3.09B
Cash79.38M90.76M73.52M120.34M309.66M250.88M1.28B1.08B1.26B
Total Debt1.00M10.50M137.87M39.09M46.58M52.59M89.86M11.29M19.40M
Net Debt-78.38M-80.26M64.35M-81.25M-263.08M-198.29M-1.19B-1.07B-1.25B

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow12.91M18.63M54.90M148.24M181.39M367.46M689.06M743.39M975.30M
Investing Cash Flow-22.46M-28.61M-68.02M730.12K-1.11B-134.53M581.90M-617.79M-579.80M
Financing Cash Flow258.81K20.90M-3.23M-101.62M1.12B-294.60M-246.36M-307.90M-226.67M
Capital Expenditure25.26M32.20M67.56M44.20M167.38M143.21M202.03M650.24M285.59M
Free Cash Flow-12.35M-13.56M-12.67M104.04M14.01M224.25M487.03M93.15M689.71M
Dividends Paid461.19K268.26K5.97M1.41M33.34M66.67M112.22M133.97M170.19M
FCF to OCF-95.65%-72.80%-23.07%70.18%7.72%61.03%70.68%12.53%70.72%
Dividend Paid to FCF-3.73%-1.98%-47.10%1.36%237.93%29.73%23.04%143.83%24.68%

Earnings

Report DateApr 26, 2021Aug 24, 2021Oct 28, 2021Feb 24, 2022Apr 28, 2022Aug 29, 2022Oct 26, 2022Apr 27, 2023Jun 30, 2025Oct 24, 2025Mar 24, 2026Mar 31, 2026Aug 19, 2026
EPS Estimate--------1.631.561.661.611.80
EPS Actual0.710.940.770.740.991.361.501.46-1.351.331.612.15
Surprise----------13.46%-19.88%-0.04%19.44%
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-market-Pre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap35.13B
Enterprise Value33.34B
Trailing P/E37.61
Forward P/E0.00
Price / Sales12.13
Price / Book11.26
EPS6.60
Book Value22.18
Revenue (TTM)2.90B
Gross Profit (TTM)2.10B
EBITDA1.12B
Profit Margin32.20%
Operating Margin39.42%
Return on Equity30.82%
Return on Assets18.43%
Shares Outstanding141.53M
Shares Float73.49M
Beta-0.37
Dividend Yield0.40%
Dividend Rate1.00
Payout Ratio15.53%

Dividends

20261×
1.00May 14, 2026
20251×
1.21Jun 19, 2025
20241×
1.38Jul 26, 2024
20231×
0.78May 29, 2023
20221×
0.48Apr 19, 2022
20211×
0.24Jun 4, 2021

Stock Splits

  • Jun 19, 20251.45:1
  • Jul 26, 20241.45:1